Autologous human adipose tissue derived bone tissue therapy - Bonus BioGroup

Drug Profile

Autologous human adipose tissue derived bone tissue therapy - Bonus BioGroup

Alternative Names: Bone graft for maxillofacial applications - Bonus BioGroup; BonoFill; BonoFill-II; HATDCs - Bonus BioGroup; Human Adipose Tissue Derived Cells - Bonus BioGroup

Latest Information Update: 23 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bonus BioGroup
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bone disorders

Most Recent Events

  • 23 Mar 2017 Phase-I/II development for Bone disorders (maxillofacial) is ongoing in Israel (Implant)
  • 24 Jan 2017 BonusBio Group plans a phase I/II trial for Bone disorders in Israel (NCT03024008)
  • 01 Dec 2016 BonusBio Group completes a phase I/II trial in Bone disorders in Israel (Implant) (NCT02153268)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top